Best offense is defense? This sophisticated market play helps investors protect themselves from dramatic lows

Best offense is defense? This sophisticated market play helps investors protect themselves from dramatic lows


It’s a class of exchange-traded funds designed to prevent your portfolio from hitting dramatic lows — but it may require a level of sophistication.

The idea: Incorporate short-term levered plays including covered call and risk-reversal strategies in order to help investors customize their own defensive strategies similar to hedging.

However, it may come with an unintended price. According to Ben Slavin of BNY Mellon, issuers and advisors may struggle to keep up with continuous product growth and change. 

“The toolkit has expanded immensely over the last couple years, and it’s going to continue to grow,” the company’s global head of ETFs told CNBC’s “ETF Edge” last week. “That said, the negative is really trying to parse all of these different products. Really understand what you’re owning and explain that to investors or even advisors who are struggling to keep up with the nuances between these products.”

Liquidity providers and asset servicers may experience difficulties with product expansion as well, he added.

Yet, it may still benefit investors with low-risk appetites.

Andrew McOrmond, managing director at WallachBeth Capital, joined Slavin on “ETF Edge” to explain how investors can hold defensive, risk-averse positions using leveraged products. 

Playing the levered game

Covered calls grant protection to clients looking to minimize losses, McOrmond said. These short-term levered plays better define outcomes, but in turn investors may miss out on gains.

“If you sell options, and the market moves against you, you’ll be protected — but you’re going to just reduce your upside [potential],” he explained, noting covered calls are “the only option” for risk-averse clients because hedging is complicated for the individual.

McOrmond sees the latest market rallies as a potentially good opportunity to “hedge.” In July, the Nasdaq jumped 12%, and the S&P 500 is up more than 8%.

Buffering the blow

The First Trust Cboe Vest Fund of Buffer ETFs, under the ticker BUFR, was designed to supply capital appreciation and limit downside risk for investors, according to the financial consulting company. 

“The name is perfect,” McOrmond said of the Cboe Vest Fund. “You’re buffered on both sides.”

The defensive strategy uses ladders to preserve capital, and option collars “buffer” the investment to mitigate losses investors might face.

Slavin also suggests the fund of buffer ETFs, citing interest and activity in the space.

The First Trust Cboe Vest Fund of Buffer ETFs is up more than 5% this month.

Disclosure: : Neither Andrew McOrmond nor Ben Slavin have ownership of First Trust Cboe Vest Fund of Buffer ETFs products.

Disclaimer



Source

Coinbase joining S&P 500 days after bitcoin soared past 0,000
Finance

Coinbase joining S&P 500 days after bitcoin soared past $100,000

Key Points Coinbase is joining the S&P 500, replacing Discover Financial, which is being acquired. Shares of the crypto exchange soared in extended trading after the announcement. Bitcoin eclipsed the $100,000 market last week, approaching its record reached in January. Source

Read More
After UK and China trade deals, tariff rate still highest since 1934, Yale report says
Finance

After UK and China trade deals, tariff rate still highest since 1934, Yale report says

Key Points The average effective tariff rate on imports is 17.8%, the highest since 1934, even after trade deals reached with China and the U.K. in recent days, according to the Yale Budget Lab. Levies that President Trump placed on other products and countries still remain, including a 10% tariff on almost all trading partners. […]

Read More
Stocks making the biggest moves midday: Amazon, Alibaba, Merck, Five Below, Nike and more
Finance

Stocks making the biggest moves midday: Amazon, Alibaba, Merck, Five Below, Nike and more

Check out the companies making headlines in midday trading: Drugmakers — Pharmaceutical stocks bounced back from earlier losses after an executive order aimed at bringing down drug prices was deemed not as bad as feared for the industry. Merck jumped 5%, while Pfizer , Bristol-Myers Squibb and Eli Lilly all rose more than 2%. However, […]

Read More